Johnson & Johnson (JNJ): FY25 Q2 earnings call, Jul 16, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Jul 16, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
9 matches for “Rybrevant”; 5 quoted, at least 25 words apart.
…of 21% with continued share gains and market growth. In lung cancer, RYBREVANT/LAZCLUZE delivered sales of $179 million and growth over 100%. And with sequential…
…this includes expected approvals in TAR-200 in non-muscle invasive bladder cancer, subcutaneous RYBREVANT for non-small cell lung cancer in the U.S. TREMFYA subcutaneous induction for…
…] And we're really pleased with the launch uptake thus far on RYBREVANT/LAZCLUZE in non-small cell lung cancer. In immunology, TREMFYA is off to a…
…looking forward to getting the subcutaneous administration approval for lung cancer with RYBREVANT/LAZCLUZE. And then on the med tech side, I think the really shining…
…again, this is oncology, there's a lot to talk about last on RYBREVANT/LAZCLUZE so a quick update. The launch is going very well. As a…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-07-16:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-07-16:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP